Cereno Scientific

The shares of Series B will continue to be traded under the ticker CRNO B and ISIN code SE0008241558. No new shares will be issued in connection with the admission to trading on Nasdaq First North. The current shareholders in Cereno do not need to take any measures in connection with the marketplace change.

“This is a pivotal day for the Cereno team, as we proudly celebrate a remarkable milestone on our growth journey. We have an exciting period ahead with the next major milestone for our most advanced program CS1 in the rare disease pulmonary arterial hypertension (PAH) at the end of the year. We look forward to continuing to deliver on our mission and welcome current as well as new shareholders to join us on Nasdaq First North in the effort to develop new treatments for cardiovascular disease where major unmet needs exist,” said Sten R. Sörensen, CEO of Cereno.

For further information, please contact:

Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North Growth Market (CRNO B). More information on www.cerenoscientific.com.